Sangamo Therapeutics, Inc.
SGMOSangamo Therapeutics, Inc. (formerly Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California, that develops cell and gene therapies for severe genetic diseases.
Drugs in Pipeline
9
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Plerixafor
Sickle Cell Disease
CERE-120: Adeno-Associated Virus Delivery of Neurturin
Idiopathic Parkinson's Disease
CERE-110: Adeno-Associated Virus injection Surgery
Alzheimer's Disease
TX200-TR101
Kidney Transplant Rejection
ST-920
Fabry Disease
SB-728-T
HIV
Cyclophosphamide
Human Immunodeficiency Virus (HIV)
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
Idiopathic Parkinson's Disease
SB-509
Diabetes Mellitus, Type 1
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Plerixafor | Phase 2 | Sickle Cell Disease | - | - |
CERE-120: Adeno-Associated Virus Delivery of Neurturin | Phase 2 | Idiopathic Parkinson's Disease | - | - |
CERE-110: Adeno-Associated Virus injection Surgery | Phase 2 | Alzheimer's Disease | - | - |
TX200-TR101 | Phase 2 | Kidney Transplant Rejection | - | - |
ST-920 | Phase 2 | Fabry Disease | - | - |
SB-728-T | Phase 2 | HIV | - | - |
Cyclophosphamide | Phase 2 | Human Immunodeficiency Virus (HIV) | - | - |
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) | Phase 2 | Idiopathic Parkinson's Disease | - | - |
SB-509 | Phase 2 | Diabetes Mellitus, Type 1 | - | - |